Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium® 24HR

  Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium® 24HR

Business Wire

NEW YORK -- March 28, 2014

Today the U.S. Food and Drug Administration (FDA) approved over-the-counter
Nexium^® 24HR (esomeprazole 20mg) marking a key step towards providing those
who suffer from frequent heartburn broader access to a brand doctors and
patients have trusted for years.

In 2012, Pfizer acquired exclusive global rights from AstraZeneca to market
non-prescription Nexium^®. The addition of Nexium^® 24HR to the Pfizer
Consumer Healthcare portfolio expands the breadth of categories in which we
help consumers better manage their health, and extends the value of the
world’s leading prescription acid blocker brand.

“Switching medicines, whenever appropriate, from prescription to
non-prescription status improves access, empowers consumers to care for their
own health and is an important strategy for Pfizer,” said Paul Sturman,
President, Pfizer Consumer Healthcare. “The FDA approval of Nexium^® 24HR is a
significant milestone in executing against our plan.”

We continue to work closely with AstraZeneca and retail partners to make
Nexium^® 24HR available to consumers in the U.S., with other markets in Europe
expected to follow this year.

Pfizer Inc: Working together for a healthier world™

At Pfizer, we apply science and our global resources to bring therapies to
people that extend and significantly improve their lives. We strive to set the
standard for quality, safety and value in the discovery, development and
manufacture of health care products. Our global portfolio includes medicines
and vaccines as well as many of the world's best-known consumer health care
products. Every day, Pfizer colleagues work across developed and emerging
markets to advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our responsibility as
one of the world's premier innovative biopharmaceutical companies, we
collaborate with health care providers, governments and local communities to
support and expand access to reliable, affordable health care around the
world. For more than 150 years, Pfizer has worked to make a difference for all
who rely on us. To learn more, please visit us at www.pfizer.com.

Contact:

Pfizer
Media:
Sally Beatty, 212-733-6566
or
Investors:
Ryan Crowe, 212-733-8160
 
Press spacebar to pause and continue. Press esc to stop.